Study S000829

Effectiveness of Once-weekly Exenatide (BCise) Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03970044
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 67
Start: 2019-07-02
Primary completion: 2021-06-01
Lead sponsor: Consano Clinical Research, LLC
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Exenatide 2 MG; DRUG:Dapagliflozin 10 MG
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

MAGE [14 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.